Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04683848 · ClinicalTrials.gov registry record · Phase 2

Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury

A Phase 2 study of Spinal Cord Injury, sponsored by Tanabe Pharma America.

Completed
Registry status
Phase 2
Development phase
72
Enrollment target
20
Study locations

NCT04683848 is a Phase 2 study of Spinal Cord Injury that has completed, run by Tanabe Pharma America. The registered enrollment target is 72 participants, below the 86-participant average among 99 other Spinal Cord Injury trials with a reported enrollment target (16% lower). The trial reports 20 study locations across 19 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04683848, a Phase 2 study of Spinal Cord Injury, has completed, sponsored by Tanabe Pharma America.

COMPLETED
Registry status
Phase 2
Development phase
72 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to compare the efficacy and safety of intravenous (IV) infusions of MT-3921 to placebo in subjects with acute traumatic cervical spinal cord injury. Subjects meeting eligibility criteria will enter the 6-month double-blind period. Subjects will be randomized in a 2:1 ratio to receive MT-3921 or placebo in a double blind manner.

Conditions Studied

Spinal Cord Injury

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL MT-3921

Study Locations (20)

Texas

  • Brooke Army Medical Center in San Antonio - Houston
  • The University of Texas Health Science Center at San Antonio - San Antonio

California

  • University of California Irvine - Orange

Florida

  • Tallahassee Neurological Clinic - Tallahassee

Georgia

  • Augusta University - Augusta

Kentucky

  • University of Kentucky - Lexington

Michigan

  • Spectrum Health - Grand Rapids

Mississippi

  • University of Mississippi Medical Center - Jackson

Missouri

  • Saint Louis University Hospital - St Louis

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2021-08-27
Est. Completion 2025-04-09
Phase Phase 2

Sponsor

Tanabe Pharma America

18 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04683848

The ClinicalTrials.gov registry entry for NCT04683848 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 86-participant average among 99 other Spinal Cord Injury trials with a reported enrollment target (16% lower). The listed sponsor is Tanabe Pharma America, which has 18 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Spinal Cord Injury appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04683848 reports 20 study locations spanning 19 distinct geographic areas - top geographies include Texas, California, Florida.

Frequently Asked Questions

What is clinical trial NCT04683848 about?

NCT04683848 is a clinical study titled "Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury". The purpose of this study is to compare the efficacy and safety of intravenous (IV) infusions of MT-3921 to placebo in subjects with acute traumatic cervical spinal cord injury. Subjects meeting eligibility criteria will enter the 6-month double-blind period. Subjects will be randomized in a 2:1 ra...

What is the current status of trial NCT04683848?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2021-08-27. Estimated completion is 2025-04-09.

What conditions does trial NCT04683848 study?

This clinical trial studies the following conditions: Spinal Cord Injury.

What interventions are being tested in trial NCT04683848?

The interventions under investigation include: Placebo (BIOLOGICAL), MT-3921 (BIOLOGICAL).

Who is sponsoring clinical trial NCT04683848?

This trial is sponsored by Tanabe Pharma America, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04683848 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Kentucky, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Spinal Cord Injury

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Spinal Cord Injury

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.